Authors |
Silva Kasela, Victor E Ortega, Molly Martorella, Suresh Garudadri, Anu Pasanen, Kristina L Buschur, R Graham Barr, Eugene R Bleecker, Jeffrey L Curtis, MeiLan K Han, Robert J Kaner, Fernando J Martinez, Deborah A Meyers, Robert Paine 3rd, Xingnan Li, Sally E Wenzel, NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS), NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, Charles Langelier, Prescott G Woodruff, Tuuli Lappalainen, Stephanie A Christenson
|
Abstract Text |
Coronavirus disease 2019 (COVID-19), the clinical syndrome caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, has led to a global crisis. As a respiratory virus, SARS-CoV-2 is hypothesized to gain entry into humans via the airway epithelium, where it initiates a host response that leads to the subsequent clinical syndrome. However, the particular host and environmental factors that determine individual disease courses are poorly understood. Here, we analyzed RNA-sequencing data from bronchial epithelial brushings obtained from uninfected individuals in the SPIROMICS, SARP, and MAST cohorts, to investigate how non-genetic and genetic factors affect the regulation of host genes implicated in COVID-19.
We found that expression of ACE2, the receptor of the SARS-CoV-2 Spike protein, was higher in relation to known risk factors of severe COVID-19, such as active smoking, obesity, and hypertension, potentially facilitating SARS-CoV-2 entry into host cells. In contrast, a truncated, non-binding ACE2 isoform drove an association between interferon-related inflammation and ACE2 expression. We also discovered that expression patterns of a suppressed airway immune response to early SARS-CoV-2 infection, compared to other viruses, were similar to patterns associated with obesity, hypertension, and cardiovascular disease, which may thus contribute to a COVID-19-susceptible airway environment.
To identify host genetic variants affecting COVID-19 susceptibility, we next performed expression quantitative trait (eQTL) mapping in SPIROMICS (WGS data from the TOPMed project) focusing on 496 genes implicated in SARS-CoV-2. Although the key genes, ACE2 and TMPRSS2, did not have eQTLs in bronchial epithelium, we discovered 108 COVID-19-related genes with significant eQTLs (FDR < 0.05). Querying PheWAS results and using colocalization analysis, we further identified 12 loci where the eQTL signal and immune- or respiratory-related trait likely shared a genetic cause. These respiratory infectivity-altering variants are plausible host genetic risk factors for COVID-19. For example, ERMP1 has an eQTL colocalizing with an asthma association in the UK Biobank. ERMP1 interacts with the SARS-CoV-2 protein Orf9c, and studies suggest that severe asthma is a risk factor for COVID-19 hospitalization and death.
Altogether, our findings of genetic and non-genetic factors affecting the expression of COVID-19-related genes in bronchial epithelium provide essential insights for understanding inter-individual variation of COVID-19 and developing therapeutic targets.
|